By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

The U.S Food and Drug Administration has approved Nucala, British drugmaker GSK's asthma drug, to treat some patients with a ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...